New prostate cancer combo trial ends early

NCT ID NCT03437941

Terminated Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39 men with advanced disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma Kennedy disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Detroit

Detroit, Michigan, 48201, United States
London

London, England, W1T7HA, United Kingdom
Madison

Madison, Wisconsin, 53792, United States
New York

New York, New York, 10065, United States
Portland

Portland, Oregon, 97239, United States
Scottsdale

Scottsdale, Arizona, 85258, United States
Southampton

Southampton, England, SO16 6YD, United Kingdom
Sutton

Sutton, Surrey, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.